- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04680676
A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis
A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging, Proof-of-concept Trial of BI 730357 Given for 12 Weeks in Patients With Active Psoriatic Arthritis
This study is open to adults with active psoriatic arthritis who have tender and swollen joints. The purpose of this study is to find out whether a medicine called BI 730357 helps to reduce symptoms and to prevent damage to joints.
Three different doses of BI 730357 are tested. Participants are put into 4 groups by chance. Participants in 3 of the 4 groups take BI 730357. Participants in the fourth group take placebo. Participants take BI 730357 or placebo as tablets once a day. Placebo tablets look like BI 730357 tablets but do not contain any medicine.
Participants are in the study for about 4.5 months. During this time, they visit the study site about 8 times. At these visits, doctors check whether the swelling of inflamed joints has changed. The results between the BI 730357 and placebo groups are then compared. Doctors also regularly check the general health of the participants.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Age ≥ 18* years and ≤ 75 years at screening, males or females
-- Except in countries where the minimum age of consent is greater than 18, in which case the minimum age is the minimum age of consent.
- Signed and dated written informed consent in accordance with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
- Have Psoriatic Arthritis (PsA) symptoms for ≥ 6 months prior to screening, as assessed by the investigator
- Have PsA on the basis of the Classification Criteria for Psoriatic Arthritis (CASPAR) with peripheral symptoms at screening visit, as assessed by the investigator
- Have ≥ 3 tender joints and ≥ 3 swollen joints at screening and randomisation visits, as assessed by the investigator
- At least one Psoriasis (PsO) skin or nail lesion or a documented personal history of PsO at screening, as assessed by the investigator
If patients receive concurrent PsA treatments, these need to be on stable doses as below:
- For patients receiving Methotrexate (MTX): patient has received treatment for ≥ 3 months, with stable dose and stable route of administration for ≥ 4 weeks prior to randomisation to End Of Observation (EOO); patients on MTX should be taking folic acid supplementation according to local standard of care before randomisation and during the trial to minimize the likelihood of MTX associated toxicity
- For patients receiving oral corticosteroids: the patient must be on a stable dose for ≥ 2 weeks prior to randomisation to EOO
- For patients receiving non-steroidal anti-inflammatory drugs (NSAIDs) or paracetamol/acetaminophen Pro re nata (PRN): the patient must be on stable dose for ≥ 2 weeks prior to randomisation to EOO
- Women of child-bearing potential (A woman is considered of childbearing potential, i.e., fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Tubal ligation is NOT a method of permanent sterilisation. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. Such methods should be used throughout the study and the patient must agree to periodic pregnancy testing during participation in the trial. There are no specific contraceptive requirements for male participants.
Patients (males or females) following the national regulatory guidelines regarding contraception if receiving MTX as background therapy.
Exclusion Criteria:
- Major chronic inflammatory or connective tissue disease other than PsA (e.g. rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, Lyme disease, gout) or fibromyalgia, as assessed by the investigator
- Active uveitis or uveitis within 4 weeks prior to randomisation, assessed by the investigator
- Suspected or diagnosed inflammatory bowel disease, assessed by the investigator
- Previous exposure to BI 730357
- Prior use of any therapeutic agent directly targeted to Interleukin (IL)-12/23, IL-23 or IL-17
- Prior use of more than two different Tumor necrosis factor inhibitor (TNFi) agents
Use of the following treatments:
- TNFi agents (including, infliximab, adalimumab, certolizumab pegol or golimumab) within 8 weeks prior to randomisation
- Etanercept within 4 weeks prior to randomisation
- Leflunomide without cholestyramine wash-out within 8 weeks prior to randomisation
- Systemic non-biologic medications for PsA or PsO (including traditional Disease-Modifying Antirheumatic Drugs (DMARDs) apremilast, a Janus Kinase (JAK) inhibitor or leflunomide with cholestyramine wash-out) or photochemotherapy within 4 weeks prior to randomisation
- Intraarticular injections (including steroids) and intramuscular or intravenous corticosteroid treatment within 4 weeks prior to randomisation
- Topical PsO medications and phototherapy within 2 weeks prior to randomisation
- Low and high potency opioid analgesics (e.g. tramadol, methadone, hydromorphone, morphine) within 2 weeks prior to randomisation
- Live vaccination ≤ 12 weeks prior to randomisation, or any plan to receive a live vaccination during the conduct of this study. Bacillus Calmette-Guérin (BCG) vaccination is restricted 1 year prior to randomisation through EOO visit.
- further exclusion criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
Placebo
|
EXPERIMENTAL: BI 730357 - low dose
|
BI 730357
|
EXPERIMENTAL: BI 730357 - medium dose
|
BI 730357
|
EXPERIMENTAL: BI 730357 - high dose
|
BI 730357
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
American College of Rheumatology (ACR) 20 response at week 12
Time Frame: at week 12
|
ACR 20 is a binary outcome (Yes, No) with 'yes' indicating improvements of the symptoms.
|
at week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ACR 50 response at Week 12
Time Frame: at week 12
|
ACR 50 is a binary outcome (Yes, No) with 'yes' indicating improvements of the symptoms.
|
at week 12
|
ACR 70 response at Week 12
Time Frame: at week 12
|
ACR 70 is a binary outcome (Yes, No) with 'yes' indicating improvements of the symptoms.
|
at week 12
|
Change in Tender Joint Count at Week 12 as compared to baseline
Time Frame: at week 12
|
Change in Tender Joint Count at Week 12 as compared to baseline, with a maximum possible range between -68 to 68 with higher values indicating a worsening of the symptoms.
|
at week 12
|
Change in Swollen Joint Count at Week 12 as compared to baseline
Time Frame: at week 12
|
Change in Swollen Joint Count at Week 12 as compared to baseline, with a maximum possible range between -66 to 66 with higher values indicating a worsening of the symptoms.
|
at week 12
|
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12 as compared to baseline
Time Frame: at week 12
|
HAQ-DI score as compared to baseline with a maximum possible range between -3 and 3 with higher values indicating a worsening of the symptoms.
|
at week 12
|
Psoriasis Area and Severity Index (PASI)75 response at Week 12, assessed in patients with a ≥ 3% baseline Psoriasis (PsO) Body Surface Area (BSA)
Time Frame: at week 12
|
PASI75 is a binary outcome (Yes, No) with 'Yes' indicating improvements of the symptoms.
|
at week 12
|
Adverse Events
Time Frame: up to 14 weeks
|
up to 14 weeks
|
|
Treatment Emergent Adverse Events
Time Frame: up to 14 weeks
|
up to 14 weeks
|
|
Serious Adverse Events
Time Frame: up to 14 weeks
|
up to 14 weeks
|
|
Intensity of Adverse Events
Time Frame: up to 14 weeks
|
Intensity of adverse events will be assessed by Rheumatology Common Toxicity Criteria (RCTC) version 2.0. The RCTC criteria consist of 4 grades (1 = mild to 4 = life-threatening) with higher grades indicating a worsening of the symptoms. |
up to 14 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1407-0004
- 2019-003182-17 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:
- studies in products where Boehringer Ingelheim is not the license holder;
- studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;
- studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).
For more details refer to: https://www.mystudywindow.com/msw/datasharing
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthritis, Psoriatic
-
AmgenRecruitingActive Juvenile Psoriatic ArthritisSpain, United Kingdom, Turkey, Belgium, France, Greece, Italy, Austria, Germany, Netherlands, Poland, Portugal, Romania, Lithuania, South Africa
-
Universitätsklinikum Hamburg-EppendorfBristol-Myers Squibb; Eli Lilly and Company; UCB Pharma; Merck Sharp & Dohme LLC; AbbVi... and other collaboratorsRecruiting
-
Sun Pharmaceutical Industries LimitedActive, not recruitingActive Psoriatic ArthritisUnited States, Australia, Czechia, Germany, India, Japan, Korea, Republic of, Poland, Spain
-
AbbVieActive, not recruitingPsoriatic Arthritis (PsA)United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
-
Sun Pharmaceutical Industries LimitedCompleted
-
Bristol-Myers SquibbCompletedActive Psoriatic ArthritisSpain, United States, Hungary, Germany, Poland, United Kingdom, Russian Federation, Italy, Czechia
-
Bristol-Myers SquibbCompletedPsoriatic Arthritis (PsA)Germany
-
Pope Research CorporationAmgenWithdrawn
-
Sun Pharmaceutical Industries LimitedRecruitingActive Psoriatic ArthritisUnited States, Australia, Czechia, Estonia, Korea, Republic of, Poland, Slovakia, Spain, Taiwan, Germany, Italy, India, Canada
-
Humanis Saglık Anonim SirketiCompletedPsoriasis and Psoriatic ArthritisIndia
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States